ARTELO BIOSCIENCES, INC. Payments to Acquire Marketable Securities
ARTELO BIOSCIENCES, INC. (ARTL) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 8-K filed 2026-03-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-17
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for the quarter ending 2025-06-30 was $0.00.
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for fiscal 2022 was $12.72M.
- ARTELO BIOSCIENCES, INC. payments to acquire marketable securities for fiscal 2021 was $6.10M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 4 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 8-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | $0.00 8-K · filed 2025-07-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $481.00K 8-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $481.00K 10-Q · filed 2025-11-12 | $1.43M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $481.00K 10-Q · filed 2025-08-13 | $1.43M derived: sum of 3 quarters · filed 2025-08-13 | $6.01M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $481.00K 8-K · filed 2025-07-11 | $1.43M derived: sum of 2 quarters · filed 2025-07-11 | $6.01M derived: sum of 3 quarters · filed 2025-07-11 | $8.36M derived: sum of 4 quarters · filed 2025-07-11 | |
| 2023-12-31 | $949.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $5.53M derived: sum of 2 quarters · filed 2025-07-11 | $7.88M derived: sum of 3 quarters · filed 2025-07-11 | $13.69M 8-K · filed 2025-07-11 | |
| 2023-09-30 | $4.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.93M derived: sum of 2 quarters · filed 2024-11-12 | $12.74M 10-Q · filed 2024-11-12 | $14.92M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $8.15M 10-Q · filed 2024-08-13 | $10.34M derived: sum of 3 quarters · filed 2024-08-13 | $18.19M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $5.80M 10-Q · filed 2024-05-13 | $7.99M derived: sum of 2 quarters · filed 2024-05-13 | $15.84M derived: sum of 3 quarters · filed 2024-05-13 | $16.58M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $10.04M derived: sum of 2 quarters · filed 2024-03-25 | $10.78M derived: sum of 3 quarters · filed 2024-03-25 | $12.72M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $7.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $8.60M derived: sum of 2 quarters · filed 2023-11-13 | $10.54M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $740.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.69M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $1.95M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $11.24M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $5.03M 10-Q · filed 2022-11-08 | ||||
| 2021-08-31 | $6.10M 10-K · filed 2023-03-31 | ||||
| 2021-02-28 | $510.69K 10-Q · filed 2021-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |